头颈部鳞状细胞癌患者接受免疫治疗时 TP53 改变的预后价值。
The Prognostic Value of TP53 Alteration in Patients with Head and Neck Squamous Cell Carcinoma Receiving Immunotherapy.
机构信息
Department of Otorhinolaryngology Head and Neck Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250021, People's Republic of China.
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan 250117, Shandong Province, People's Republic of China.
出版信息
Oncologist. 2022 Jul 5;27(7):e604-e605. doi: 10.1093/oncolo/oyac087.
The article by Wilson et al., published in the February 2021 issue, reported the prognostic value of circulating tumor DNA (ctDNA) sequencing in head and neck squamous cell carcinoma (HNSCC), noting TP53 as the most altered and concordant gene in ctDNA and tDNA. This Letter to the Editor further considers the role of TP53 alteration in the prognosis prediction of immunotherapy in HNSCC.
威尔逊等人的文章发表在 2021 年 2 月的期刊上，报道了循环肿瘤 DNA（ctDNA）测序对头颈鳞状细胞癌（HNSCC）的预后价值，指出 TP53 是 ctDNA 和肿瘤组织 DNA（tDNA）中改变最一致的基因。这封给编辑的信进一步探讨了 TP53 改变在 HNSCC 免疫治疗预后预测中的作用。
Zotero 插件